Johnson & JohnsonvsMicrobot Medical

JNJ and MBOT stock compared: price, dividend, valuation and results, from SEC filings.

MBOT

Microbot Medical Inc.

$0.68

Value $46M

-8.11%
MBOT's page

Johnson & Johnson (JNJ) has a market value of $652B and Microbot Medical (MBOT) $46M. Over the last year, with dividends, JNJ moved +36.6% and MBOT -64.6%. Dividend yield: JNJ 1.95%, MBOT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    MBOT$46M

    JNJ is 14,271 times MBOT

  • Revenue, 12 months

    JNJ$99.3B

    MBOT–

  • Net income, 12 months

    JNJ$16.1B

    MBOT-$19M

  • Operating margin

    JNJ–

    MBOT–

  • ROIC

    JNJ12.4%

    MBOT-15.0%

    27.4 points apart

  • P/E

    JNJ40.5

    MBOT–

  • Dividend yield

    JNJ2.0%

    MBOT0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    MBOT-88.7%

    179.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

MBOT-88.7%

10020020222023202420252026
Returns by period
PeriodJNJWith dividendsMBOTWith dividends
1 year since November 19, 2025+36.6%Price +33.6%-64.6%Price -64.6%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%-50.4%-20.8% a yearPrice -50.4%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%-88.7%-35.3% a yearPrice -88.7%
10 years since November 22, 2016+212.6%+12.1% a yearPrice +139.9%-99.6%-42.2% a yearPrice -99.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonMBOTMicrobot Medical

Valuation

JNJMBOT
Valuation
Price$270.47$0.68
Market value$652B$46M
Enterprise value (EV)$679B–
P/E40.5–
P/E, 5-year median21.9–
P/B8.00.7
EV/EBIT38.3–
Free cash flow yield3.2%–

Results and growth

JNJMBOT
Results and growth
Revenue, 12 months$99.3B–
Net income, 12 months$16.1B-$19M
Free cash flow, 12 months$20.6B-$20M
Earnings per share, 12 months$6.59-$0.26
Revenue growth, year on year6.1%–
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJMBOT
Margins and returns on capital
Gross margin67.6%–
Operating margin––
Net margin16.2%–
ROIC12.4%-15.0%
ROE19.7%-25.7%

Balance sheet

JNJMBOT
Balance sheet
Cash$17.2B$62M
Total debt$44.7B$838.0K
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJMBOT
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or MBOT

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Microbot Medical?

By market value, Johnson & Johnson ($652B) is about 14,271.4 times Microbot Medical ($46M), at today's prices.

How did JNJ and MBOT stock do over the last 10 years?

Since November 22, 2016, JNJ's price moved +139.9% and MBOT's -99.6%. With dividends: JNJ +212.6% (+12.1% a year), MBOT -99.6% (-42.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or MBOT?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Microbot Medical. Over the last twelve months they paid $5.28 and – per share.

Which is the better investment, Johnson & Johnson or Microbot Medical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.